DrugPatentWatch Database Preview
Mallinckrodt Inc Company Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the competitive landscape for MALLINCKRODT INC, and when can generic versions of MALLINCKRODT INC drugs launch?
MALLINCKRODT INC has four approved drugs.
There are thirteen US patents protecting MALLINCKRODT INC drugs.
There are forty-seven patent family members on MALLINCKRODT INC drugs in twenty countries and forty-two supplementary protection certificates in seven countries.
Summary for Mallinckrodt Inc
| International Patents: | 47 |
| US Patents: | 13 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
| Drug Master File Entries: | 67 |
| Patent Litigation for Mallinckrodt Inc: | See patent lawsuits for Mallinckrodt Inc |
Drugs and US Patents for Mallinckrodt Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | DISCN | Yes | No | 8,372,432 | Start Trial | Y | Start Trial | |||
| Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | DISCN | Yes | No | 7,976,870 | Start Trial | Start Trial | ||||
| Mallinckrodt Inc | METHADONE HYDROCHLORIDE | methadone hydrochloride | POWDER;FOR RX COMPOUNDING | 006383-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
| Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | DISCN | Yes | No | 8,992,975 | Start Trial | Y | Start Trial | |||
| Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | DISCN | Yes | No | 6,488,962 | Start Trial | Y | Start Trial | |||
| Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | DISCN | Yes | No | 8,377,453 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for MALLINCKRODT INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 7.5 mg/325 mg | ➤ Subscribe | 2014-04-03 |
Premature patent expirations for MALLINCKRODT INC
Expiration due to failure to pay maintenance fee
| Patent Number | Expiration Date |
|---|---|
| Start Trial | Start Trial |
International Patents for Mallinckrodt Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 102105136 | Start Trial |
| South Korea | 101748906 | Start Trial |
| Mexico | 2010009990 | Start Trial |
| China | 103402499 | Start Trial |
| European Patent Office | 1439826 | Start Trial |
| New Zealand | 523214 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Mallinckrodt Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1666481 | 17C1031 | France | Start Trial | PRODUCT NAME: TOFACITINIB,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,DONT LE CITRATE DE SODIUM; REGISTRATION NO/DATE: EU/1/17/1178 20170324 |
| 2932970 | 18C1043 | France | Start Trial | PRODUCT NAME: UNE COMBINAISON COMPRENANT DU DOLUTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI,EN PARTICULIER LE SEL DE SODIUM DU DOLUTEGRAVIR,ET DE LA RILPIVIRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,EN PARTICULIER LE CHLORHYDRATE DE RILPIVIRINE; REGISTRATION NO/DATE: EU/1/18/1282 20180518 |
| 0186405 | SPC/GB00/021 | United Kingdom | Start Trial | PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316 |
| 2203431 | CR 2015 00014 | Denmark | Start Trial | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119 |
| 2203431 | 92666 | Luxembourg | Start Trial | PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119 |
| 1912999 | 2014/058 | Ireland | Start Trial | PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
